Page last updated: 2024-11-07

dodecylphosphocholine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

dodecylphosphocholine: phospholipase A2 inhibitor; RN refers to chloride [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

dodecylphosphocholine : A phosphocholine that is the monododecyl ester of phosphocholine [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID644308
CHEMBL ID229565
CHEBI ID78018
SCHEMBL ID596694
MeSH IDM0092376

Synonyms (34)

Synonym
d 23170
n-dodecylphosphorylcholine
fos-choline 12
ethanaminium, 2-[[(dodecyloxy)hydroxyphosphinyl]oxy]-n,n,n-trimethyl-, inner salt
ethanaminium, 2-[[(dodecyloxy)hydroxyphosphinyl]oxy]-n,n,n-trimethyl-, inner salt (9ci)
choline, hydroxide, dodecyl hydrogen phosphate, inner salt (8ci)
2-(trimethylammonio)ethyl dodecyl phosphate
dodecylphosphocholine
29557-51-5
n-dodecylphosphocholine
ddppc
dodecyl 2-(trimethylammonio)ethyl phosphate
chebi:78018 ,
CHEMBL229565
dodecyl 2-(trimethylazaniumyl)ethyl phosphate
SCHEMBL596694
3KYQ
mfcd00674306
dodecyl phosphocholine
AKOS032947364
BCP17437
Q27147589
M5CF6282DD ,
unii-m5cf6282dd
ethanaminium, 2-(((dodecyloxy)hydroxyphosphinyl)oxy)-n,n,n-trimethyl-, inner salt
DTXSID00952050
dodecyl (2-(trimethylammonio)ethyl) phosphate
n c12pc
nc12pc
n-c12pc
foscholine-12
F14775
HY-116013
CS-0063470

Research Excerpts

Toxicity

ExcerptReferenceRelevance
", no separation between effective and toxic concentration)."( Dodecylphosphocholine-mediated enhancement of paracellular permeability and cytotoxicity in Caco-2 cell monolayers.
LeCluyse, EL; Liu, DZ; Thakker, DR, 1999
)
0.3

Bioavailability

ExcerptReferenceRelevance
"Following epidural administration, cerebrospinal fluid bioavailability of local anesthetics is low, one major limiting factor being diffusion across the arachnoid mater barrier."( Ex vivo and in vivo diffusion of ropivacaine through spinal meninges: influence of absorption enhancers.
Brandhonneur, N; Chevanne, F; Deniau, AL; Dollo, G; Estèbe, JP; Le Corre, P; Legrand, A; Ratajczak-Enselme, M, 2011
)
0.37
"Interactions of macrolide antibiotics with biological membranes contribute to their bioavailability but are also involved in the formation of phospholipidosis, which is caused by the inhibition of phospholipase A(1) activity."( Probing the interactions of macrolide antibiotics with membrane-mimetics by NMR spectroscopy.
Göbl, C; Kosol, S; Krajačić, MB; Meyer, NH; Novak, P; Rechberger, GN; Schrank, E; Wagner, GE; Zangger, K, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
" Daily dosing over 28 days in rats resulted in mild to moderate, unilateral or bilateral erosion/ulceration of the olfactory epithelium, frequently with minimal to mild, acute to sub-acute inflammation of the lamina propria at the dorsal turbinates of the nasal cavity in 2/10 males and 3/10 females in the high-dose group (0."( A novel nasal powder formulation of glucagon: toxicology studies in animal models.
Carballo, D; McInally, K; Normand, P; Piché, C; Reno, FE; Silo, S; Stotland, P; Triest, M, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
detergentA surfactant (or a mixture containing one or more surfactants) having cleaning properties in dilute solutions.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
phosphocholinesAny compound having phosphocholine as part of its structure.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Synaptobrevin homolog YKT6Rattus norvegicus (Norway rat)Kd60.000060.000060.000060.0000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID288963Toxicity assessed as haemolytic activity against human erythrocytes at 88 uM2007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
Synthesis, antifungal and antimicrobial activity of alkylphospholipids.
AID1676785Induction of membrane perturbation in DC18:1PC LUV bilayer assessed as fluorescence quench rate by measuring gramicidin mixture monomer to dimer equilibrium at 300 uM by fluorescence quenching assay2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Assessing the Perturbing Effects of Drugs on Lipid Bilayers Using Gramicidin Channel-Based
AID288958Inhibition of lipoprotein lipase activity of Cryptococcus neoformans var. grubi H99 secreted PLB1 at 25 uM by radiometric assay method2007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
Synthesis, antifungal and antimicrobial activity of alkylphospholipids.
AID288955Antifungal activity against Candida albicans ATCC 102312007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
Synthesis, antifungal and antimicrobial activity of alkylphospholipids.
AID288962Toxicity assessed as haemolytic activity against human erythrocytes at 175 uM2007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
Synthesis, antifungal and antimicrobial activity of alkylphospholipids.
AID1676775Induction of membrane perturbation in DC22:1PC LUV bilayer assessed as change in deltaG for pure gramicidin monomer to to dimer by fluorescence quenching assay (Rvb = 0 kcal/mol)2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Assessing the Perturbing Effects of Drugs on Lipid Bilayers Using Gramicidin Channel-Based
AID288956Inhibition of phospholipase B activity of Cryptococcus neoformans var. grubi H99 secreted PLB1 by radiometric assay method2007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
Synthesis, antifungal and antimicrobial activity of alkylphospholipids.
AID288966Toxicity assessed as haemolytic activity against human erythrocytes at 3.5 uM2007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
Synthesis, antifungal and antimicrobial activity of alkylphospholipids.
AID288961Toxicity assessed as haemolytic activity against human erythrocytes at 350 uM2007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
Synthesis, antifungal and antimicrobial activity of alkylphospholipids.
AID288964Toxicity assessed as haemolytic activity against human erythrocytes at 44 uM2007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
Synthesis, antifungal and antimicrobial activity of alkylphospholipids.
AID288965Toxicity assessed as haemolytic activity against human erythrocytes at 17.5 uM2007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
Synthesis, antifungal and antimicrobial activity of alkylphospholipids.
AID1676776Induction of membrane perturbation in DC22:1PC LUV bilayer assessed as change in deltaG for gramicidin mixture monomer to to dimer by fluorescence quenching assay (Rvb = 0 kcal/mol)2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Assessing the Perturbing Effects of Drugs on Lipid Bilayers Using Gramicidin Channel-Based
AID288954Antifungal activity against Cryptococcus neoformans ATCC 901122007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
Synthesis, antifungal and antimicrobial activity of alkylphospholipids.
AID1676779Induction of membrane perturbation in DC22:1PC LUV bilayer assessed as fluorescence quench rate by measuring increase in R(drug)/R(control) ratio by fluorescence quenching assay2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Assessing the Perturbing Effects of Drugs on Lipid Bilayers Using Gramicidin Channel-Based
AID1676782Induction of membrane perturbation in DC22:1PC LUV bilayer assessed as fluorescence quench rate by measuring gramicidin mixture monomer to dimer equilibrium at 300 uM by fluorescence quenching assay2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Assessing the Perturbing Effects of Drugs on Lipid Bilayers Using Gramicidin Channel-Based
AID1676784Induction of membrane perturbation in DC20:1PC LUV bilayer assessed as fluorescence quench rate by measuring gramicidin mixture monomer to dimer equilibrium at 300 uM by fluorescence quenching assay2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Assessing the Perturbing Effects of Drugs on Lipid Bilayers Using Gramicidin Channel-Based
AID1676774Induction of membrane perturbation in DC22:1PC LUV bilayer assessed as effect on potential of mean force by measuring reduction in deltaG for gramicidin mixture monomer to dimer and pure gramicidin-bilayer by fluorescence quenching assay2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Assessing the Perturbing Effects of Drugs on Lipid Bilayers Using Gramicidin Channel-Based
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2010Molecular cell, Feb-12, Volume: 37, Issue:3
Lipid-Induced conformational switch controls fusion activity of longin domain SNARE Ykt6.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (358)

TimeframeStudies, This Drug (%)All Drugs %
pre-199020 (5.59)18.7374
1990's67 (18.72)18.2507
2000's119 (33.24)29.6817
2010's143 (39.94)24.3611
2020's9 (2.51)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (0.83%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other359 (99.17%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]